Tirzepatide

PRODUCT DESCRIPTION
Peptide Name: Tirzepatide
 
RESEARCH SUMMARY
Dual incretin receptor activation.
Significant body weight reduction.
Glycemic control efficiency improvement.
Insulin sensitivity enhancement support.
Metabolic dysfunction management potential.
 
Chemical Name: L-Serinamide, L-tyrosyl-2-methylalanyl-L-alpha-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-tyrosyl-L-seryl-L-isoleucyl-2-methylalanyl-L-leucyl-L-alpha-aspartyl-L-lysyl-L-isoleucyl-L-alanyl-L-glutaminyl-N6
CAS Number: 2023788-19-2
 
Tirzepatide is a first-in-class dual agonist of both the glucagon-like peptide-1 (GLP-1) and the glucose-dependent insulinotropic polypeptide (GIP) receptors. This 39-amino acid synthetic peptide is engineered to mimic the effects of these two natural incretin hormones, which are released from the gut in response to food intake. By acting on both receptors simultaneously, Tirzepatide provides a synergistic approach to regulating metabolic health. Its unique structure includes a C20 fatty diacid moiety that allows it to bind to albumin, significantly extending its half-life for research applications.
 
Researched Benefits:
Blood Sugar Regulation: Research shows a high efficacy in lowering HbA1c levels by stimulating insulin secretion in a glucose-dependent manner.
Weight Management: Studies indicate substantial reduction in body mass and adiposity, often exceeding the results seen with single-receptor agonists.
Appetite Suppression: Investigated for its ability to modulate brain signaling related to hunger, leading to reduced caloric intake.
Cardiometabolic Health: Observed to improve lipid profiles and reduce blood pressure in subjects with metabolic syndrome.
 
KIT INCLUDES:
1x Peptide Vial
1x 10ml Sterile Water
1x Reconstitution Kit
 
DISCLAIMER
SAHPRA DISCLAIMER: This product has not been evaluated by the South African Health Products Regulatory Authority (SAHPRA). This product is not intended to diagnose, treat, cure, or prevent any disease.
RESEARCH USE ONLY: This product is sold strictly for laboratory research and analytical purposes. It is not for human or veterinary use.
 
RESEARCH STUDIES
Frias, J.P., et al. (2018). Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes. The Lancet. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32260-8/fulltext
Jastreboff, A.M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
Rosenstock, J., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). The Lancet. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01324-6/fulltext